Toxic epidermal necrolysis: current evidence, practical management and future directions

Area of Science:

• Immunodermatology
• Pharmacogenomics
• Cellular toxicology

Background:

• Toxic epidermal necrolysis (TEN) is a rare, severe cutaneous adverse drug reaction.
• Pathogenesis remains incompletely understood, with conflicting proposed mechanisms.
• High mortality rates underscore the need for improved understanding and treatment.

Purpose of the Study:

• To review and synthesize current literature on TEN pathogenesis and drug reactions.
• To propose a composite model for TEN pathogenesis.
• To evaluate therapeutic interventions and evidence for their efficacy.

Main Methods:

• Comprehensive literature review of TEN and drug reaction pathogenesis.
• Development of a composite model integrating known pathways.
• Analysis of evidence for various therapeutic strategies.

Main Results:

• TEN is proposed as an HLA class I-restricted, drug-specific sensitivity involving CD8+ cytotoxic T lymphocytes (CTLs).
• Cytotoxicity is mediated by CTL granzyme and death receptor ligands (DR-L), notably Fas ligand (FasL) and potentially tumor necrosis factor (TNF).
• An amplification sequence involving further DR-L expression and potential antiapoptotic pathway upregulation is suggested.

Conclusions:

• No single treatment is definitively effective; a multifaceted regimen is indicated.
• Treatment should target immune pathways, including drug elimination, immunosuppression, and apoptosis modulation.
• Specialized nursing care is crucial for managing this severe condition.